Skip to content
The Kids Research Institute Australia logo
Donate

Search

Asthma

Respiratory disease is a global issue and international networks are critical to informing best-practice approaches to the clinical care and management of childhood respiratory health.

Respiratory Research Teams

The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.

The Kids Research Institute Australia researchers awarded $11 million to support vital child health research

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.

Campaign designed to improve the lung health of Aboriginal children

A public health campaign to raise awareness about the dangers of chronic wet cough in Aboriginal children is helping to improve detection, diagnosis and management of the condition.

Fighting lung disease

Culturally secure intervention to facilitate medical follow up for Aboriginal children, after being hospitalised with chest infections, have proven to improve long-term lung health outcomes.

Giving kids with CF a chance at a longer, healthier life

COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.

Funding boost for cancer, antimicrobial resistance, and pain management treatments

The Kids Research Institute Australia researchers will share in $2.3 million awarded by the Western Australian Department of Health Innovation Seed Fund.

Research into innovative treatments for asthma and antibiotic-resistant infections fuelled by Stan Perron Charitable Foundation grants

New funding from the Stan Perron Charitable Foundation will support research into innovative treatments for antibiotic-resistant infections and asthma in children, led by Wal-yan Respiratory Research Centre researchers. 

Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial

We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.

Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry

Measurement of lung volumes across the life course is critical to the diagnosis and management of lung disease. The aim of the study was to use the Global Lung Function Initiative methodology to develop all-age multi-ethnic reference equations for lung volume indices determined using body plethysmography and gas dilution techniques.